Immunization Schedule
This graph shows the total number of publications written about "Immunization Schedule" by people in the URMC Research Network by year, and whether "Immunization Schedule" was a major or minor topic of these publication.
Below are the most recent publications written about "Immunization Schedule" by people in Profiles.
-
McElligott JT, Roberts JR, O'Brien ES, Freeland KD, Kolasa MS, Stevenson J, Darden PM. Improving immunization rates at 18 months of age: implications for individual practices. Public Health Rep. 2011 Jul-Aug; 126 Suppl 2:33-8.
-
Poehling KA, Szilagyi PG. Not just for kids: new paradigms for vaccine delivery in pediatrics. Acad Pediatr. 2009 Sep-Oct; 9(5):293-4.
-
Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics. 2009 Jan; 123(1):301-12.
-
Szilagyi PG, Fairbrother G, Griffin MR, Hornung RW, Donauer S, Morrow A, Altaye M, Zhu Y, Ambrose S, Edwards KM, Poehling KA, Lofthus G, Holloway M, Finelli L, Iwane M, Staat MA. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Arch Pediatr Adolesc Med. 2008 Oct; 162(10):943-51.
-
Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008 Sep 1; 198(5):635-41.
-
Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis. 2008 Feb 15; 197(4):580-3.
-
Pichichero ME, Bernstein H, Blatter MM, Schuerman L, Cheuvart B, Holmes SJ. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. J Pediatr. 2007 Jul; 151(1):43-9, 49.e1-2.
-
Pichichero ME. Who should get the HPV vaccine? J Fam Pract. 2007 Mar; 56(3):197-202.
-
Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006 Oct 28; 368(9546):1495-502.
-
Szilagyi PG, Griffin MR, Shone LP, Barth R, Zhu Y, Schaffer S, Ambrose S, Roy J, Poehling KA, Edwards KM, Walker FJ, Schwartz B. The impact of conjugate pneumococcal vaccination on routine childhood vaccination and primary care use in 2 counties. Pediatrics. 2006 Oct; 118(4):1394-402.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
